Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Liposarcoma 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1

Interventions

Doxorubicin 9Ifosfamide 8Radiotherapy 6Neoadjuvant Therapy 3Chemotherapy, Adjuvant 3Trabectedin 2Filgrastim 2Etoposide 2pembrolizumab 1pegfilgrastim 1olaratumab 1milademetan 1indolepropanol phosphate 1brigimadlin 1X-Rays 1Watchful Waiting 1Vincristine 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy, Conformal 1Observation 1Epirubicin 1Diathermy 1Dactinomycin 1Dacarbazine 1Cyproheptadine 1Cyclophosphamide 1Combined Modality Therapy 1Carboplatin 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Liposarcoma × brigimadlin × Clear all
NCT06058793 2026-01-09

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

Boehringer Ingelheim

Phase 3 Completed
138 enrolled
Sarcoma

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡